Giuseppe Del Giudice | Translational Science Leader

Giuseppe Del Giudice, Translational Science Leader, GSK

Translational Science Leader at GSK Vaccines Srl, Siena, Italy (previously Novartis Vaccines), he is responsible of activities (mainly related to human immunology and translational research) focusing on the understanding of how vaccine-related (adjuvants, formulations, delivery, etc) and host-related factors (age, genetic makeup, environment, pharmaceutical treatments, etc) can affect positively or negatively the immune response to vaccines against several viral and bacterial diseases, more specifically in the areas of influenza, vaccine adjuvants, conjugated vaccines, vaccination at the extremes of age, pertussis, meningitis, staphylococcal infections, etc. From 1996 and 2005, he was responsible of the preclinical research at Chiron Vaccines, Siena, mainly in the areas of the development of bacterial vaccines and of  mucosal vaccines. Before, he spent 12 years in Switzerland studying the immune response to malaria parasites first at the University of Geneva, then at the University of Lausanne, where he got the position of Professeur Agrégé. Concomitantly he was appointed medical officer (staff member) at the World Health Organization Headquarters, Division of Communicable Diseases. He received his MD degree at the University of Milan, where he also got the Specialisation in Infectious Diseases. He then received his PhD in Immunology at the University of Geneva. He is author and co-author of over 270 publications, member of several international scientific societies, and member of international non-governmental non-profit scientific committees.


DC Co-conference Day 2 April 4 @ 09:10

Areas of interest for big pharma: External collaborative research and partnering opportunities for vaccine development

More speakers from Merck, Pfizer, biotechs and academics to join

DC Co-conference Day 2 April 4 @ 11:40

Biomarkers of vaccine safety

  • The need for specific trial design
  • Systemic vs local markers
  • The experience of Biovacsafe

DC Co-conference Day 3 April 5 @ 09:10

Results on developing a new pertussis vaccine – Opportunities for maternal

·         The need for a new pertussis vaccine with longer lasting immunity

·         Challenges in making an effective pertussis vaccines: Cyclical by nature, waning immunity, asymptomatic carriers

back to speakers